CoChat

SHP1 Protein-tyrosine Phosphatase Inhibits gp91PHOXand p67PHOX Expression by Inhibiting Interaction of PU.1, IRF1, Interferon Consensus Sequence-binding Protein, and CREB-binding Protein with Homologous Cis Elements in the CYBB andNCF2 Genes

Open access
Kautz, Bryan, Kakar, Renu, David, Ebenezer, Eklund, Elizabeth A. · 2001 · Journal of Biological Chemistry

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 1 of the 25 sources its claims cite were checked for support.

Abstract

The CYBB and NCF2 genes encode the phagocyte respiratory burst oxidase proteins, gp91PHOX and p67PHOX. Previously, we identified homologous CYBB and NCF2 cis elements that are necessary for lineage-specific transcription during late myeloid differentiation. We determined that these homologous cis elements are activated by PU.1, IRF1, interferon consensus sequence-binding protein (ICSBP), and the CREB-binding protein (CBP). Since expression of PU.1 and ICSBP is lineage-restricted, our investigations identified a mechanism of lineage-specific CYBB and NCF2 transcription. Since PU.1, IRF1, ICSBP, and CBP are expressed in undifferentiated myeloid cells, our investigations did not determine the mechanism of differentiation stage-specific CYBB and NCF2 transcription. In the current investigations, we determine that SHP1 protein-tyrosine phosphatase (SHP1-PTP) inhibits gp91PHOX and p67PHOX expression, in undifferentiated myeloid cell lines, by decreasing interaction of PU.1, IRF1, ICSBP, and CBP with the CYBB and NCF2 genes. We also determine that IRF1 and ICSBP are tyrosine-phosphorylated during interferon gamma differentiation of myeloid cell lines, and we identify IRF1 and ICSBP tyrosine residues that are necessary for CYBB and NCF2 transcription. Therefore, these investigations identify a novel mechanism by which SHP1-PTP antagonizes myeloid differentiation and determine that tyrosine phosphorylation of IRF1 and ICSPB mediates stage-specific transcriptional activation in differentiating myeloid cells.

Overview

CoChat Summary

TL;DR

SHP1 protein-tyrosine phosphatase activity in undifferentiated myeloid cells inhibits CYBB and NCF2 transcription and gp91PHOX/p67PHOX expression by reducing tyrosine phosphorylation of IRF1 and ICSBP and decreasing assembly of the PU.1/IRF1/ICSBP/CBP HAF1a complex. IFNγ differentiation lowers SHP1-PTP activity and increases IRF1/ICSBP tyrosine phosphorylation, linking a phosphatase/kinase balance to differentiation stage-specific oxidase gene transcription.

Key findings

  • IFNγ treatment of U937 cells decreased SHP1-PTP activity by 46.1 ± 6.7% (n = 3, p = 0.017), while total PTP activity increased 326 ± 30% (n = 6, p < 0.01); SHP1 protein abundance modestly decreased.
  • Dominant-negative CS453-SHP1 increased gp91PHOX and p67PHOX mRNA in undifferentiated U937 cells, whereas SHP1 overexpression decreased these mRNAs in IFNγ-treated cells; SHP1-PTP inhibition did not alter gp91PHOX mRNA stability (8-h half-life, p = 0.84) or the more stable p67PHOX message.
  • CS453-SHP1 increased CYBB promoter reporter expression by 143 ± 12.8% (n = 3, p = 0.026) and NCF2 promoter reporter expression by 129 ± 10.4% (n = 3, p = 0.056); SHP1 overexpression decreased CYBB by 41.8 ± 6.6% (n = 3, p = 0.174) and NCF2 by 39.4 ± 5.5% (n = 3, p = 0.196). For the HAF1 reporter, CS453-SHP1 increased activity by 79.6 ± 17.7% in undifferentiated cells (n = 5, p = 0.027), and SHP1 overexpression decreased activity by 49.3 ± 13.3% in undifferentiated cells (n = 5, p = 0.026) and by 61.8 ± 19.6% in IFNγ-treated cells (n = 3, p = 0.037).
  • IRF1 and ICSBP tyrosine phosphorylation increased with IFNγ differentiation and with CS453-SHP1, and SHP1 treatment decreased tyrosine phosphorylation of in vitro translated IRF1 and ICSBP. Mutating conserved Tyr109 in IRF1 or Tyr95 in ICSBP impaired HAF1 activation: Y109F IRF1 lost synergy with PU.1 + ICSBP (59.1% less reporter expression, n = 14, p < 0.0031), and Y95F ICSBP with PU.1 + IRF1 was 62.5% less than wild type (n = 16, p = 0.0003).

Methods

  • Human U937 myelomonocytic and PLB985 promyelocytic cell lines were used; U937 cells were treated with or without IFNγ (200 or 1,000 units/ml) and stably transfected to overexpress SHP1, dominant-negative CS453-SHP1, IRF1, Y109F IRF1, ICSBP, or Y95F ICSBP.
  • Reporter assays used CYBB promoter, NCF2 promoter, or artificial HAF1-element constructs; EMSA used CYBB/NCF2 HAF1 probes with nuclear proteins, PTP inhibitors, Yop phosphatase, or purified SHP1; immunoprecipitation/Western blotting assessed tyrosine phosphorylation; PTP assays measured SHP1 activity; Northern blots with actinomycin D assessed mRNA stability; GST pull-down assays tested protein-protein interactions with in vitro translated proteins.
  • Reporter activity was measured by CAT assays normalized to β-galactosidase, with densitometry for Northern blots and reported n and p values.

Limitations

  • The paper states it has not directly demonstrated that the conserved tyrosine residues in IRF1 and ICSBP are phosphorylated during IFNγ-induced U937 differentiation; identification of the phosphorylated residues is planned. It also notes that an unidentified PTP activated by SHP1-PTP could dephosphorylate IRF1 and ICSBP, so IRF1/ICSBP may not be direct SHP1 substrates.
  • Evident from the text: most mechanistic experiments use the U937 cell line, overexpression systems, and in vitro binding/phosphorylation assays rather than primary myeloid cells or in vivo models; the authors also note that phosphorylation in rabbit reticulocyte lysate may differ from myeloid cells.
  • Evident from the reported statistics: several reporter effects were not statistically significant, including the NCF2 promoter increase with CS453-SHP1 (p = 0.056) and the SHP1-overexpression decreases in CYBB and NCF2 promoter reporters (p = 0.174 and p = 0.196).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1074/jbc.m103381200

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIG. 1 PTP activity antagonizes in vitro binding of the HAF1a complex to the CYBB HAF1 cis element. A, treatment of U937 cells with sodium orthovanadate increases binding of the HAF1a complex to the CYBB HAF1 cis element. Nuclear proteins were isolated from U937 cells with or without sodium orthovanadate treatment (a PTP inhibitor) and with or without IFN 𝛄 treatment. EMSA was performed with the CYBB HAF1 cis element probe, and nuclear proteins were isolated under the following conditions: lane 1, no sodium orthovanadate, no IFN 𝛄 ; lane 2, no sodium orthovanadate, 48 h of IFN 𝛄 ; lane 3, sodium orthovanadate, no IFN 𝛄 ; lane 4, sodium orthovanadate, 48 h of IFN 𝛄 . The HAF1 complex is indicated with an arrow and the HAF1a complex with an arrowhead. The fast migrating complex is PU.1 monomer. PTP inhibitor treatment of U937 cells induces almost as much HAF1a binding as IFN 𝛄 differentiation. In contrast, HAF1 complex and PU.1 monomer binding are not altered. B, treatment of nuclear proteins from differentiated U937 cells with Yop tyrosine phosphatase decreases HAF1a complex binding. Nuclear proteins were isolated from U937 cells, with or without IFN 𝛄 treatment. U937 nuclear proteins were incubated with or without Yop protein-tyrosine phosphatase. EMSA were performed with the CYBB HAF1 cis element probe and nuclear proteins under the following conditions: lane 1, no IFN 𝛄 , no Yop ; lane 2, 48 h ofIFN 𝛄 , no Yop ; lane 3, 48 h of IFN 𝛄 , Yop ; lane 4, 48 h of IFN 𝛄 , sham incubation in Yop buffer. The HAF1 complex is indicated by the arrow, and the HAF1a complex by the arrowhead. Yop treatment decreases binding of the HAF1a complex but does not affect the HAF1 complex or PU.1 monomer.
FIG. 1 PTP activity antagonizes in vitro binding of the HAF1a complex to the CYBB HAF1 cis element. A, treatment of U937 cells with sodium orthovanadate increases binding of the HAF1a complex to the CYBB HAF1 cis element. Nuclear proteins were isolated from U937 cells with or without sodium orthovanadate treatment (a PTP inhibitor) and with or without IFN 𝛄 treatment. EMSA was performed with the CYBB HAF1 cis element probe, and nuclear proteins were isolated under the following conditions: lane 1, no sodium orthovanadate, no IFN 𝛄 ; lane 2, no sodium orthovanadate, 48 h of IFN 𝛄 ; lane 3, sodium orthovanadate, no IFN 𝛄 ; lane 4, sodium orthovanadate, 48 h of IFN 𝛄 . The HAF1 complex is indicated with an arrow and the HAF1a complex with an arrowhead. The fast migrating complex is PU.1 monomer. PTP inhibitor treatment of U937 cells induces almost as much HAF1a binding as IFN 𝛄 differentiation. In contrast, HAF1 complex and PU.1 monomer binding are not altered. B, treatment of nuclear proteins from differentiated U937 cells with Yop tyrosine phosphatase decreases HAF1a complex binding. Nuclear proteins were isolated from U937 cells, with or without IFN 𝛄 treatment. U937 nuclear proteins were incubated with or without Yop protein-tyrosine phosphatase. EMSA were performed with the CYBB HAF1 cis element probe and nuclear proteins under the following conditions: lane 1, no IFN 𝛄 , no Yop ; lane 2, 48 h ofIFN 𝛄 , no Yop ; lane 3, 48 h of IFN 𝛄 , Yop ; lane 4, 48 h of IFN 𝛄 , sham incubation in Yop buffer. The HAF1 complex is indicated by the arrow, and the HAF1a complex by the arrowhead. Yop treatment decreases binding of the HAF1a complex but does not affect the HAF1 complex or PU.1 monomer.CC-BY · From the PDF
FIG. 2 Inhibition of SHP1-PTP activity increases gp91 PHOX and p67 PHOX mRNA abundance. A, SHP1-PTP protein is predominantly nuclear in U937 cells, and protein abundance decreases during IFN 𝛄 -induced differentiation. U937 cells were incubated for 48 h with or without IFN 𝛄 differentiation. Nuclear and cytoplasmic proteins were isolated and separated by SDS-PAGE (50 𝛍 g), and Western blots were probed with anti-SHP1 antibody. Nuclear ( NE ) and cytoplasmic ( CE ) fractions and IFN 𝛄 treatment are as indicated. IFN 𝛄 treatment results in modest decrease in nuclear SHP1 protein. B, SHP1 and CS453-SHP1 are overexpressed in U937 stable transfectants. U937 cells were stably transfected with vectors to overexpress SHP1, dominant negative SHP1 (CS453), or control pSR 𝛂 vector. Cell lysates were separated by SDSPAGE (10 𝛍 g) and probed with anti-SHP1 antibody. Increased immunoreactive SHP1 is present in cells overexpressing either SHP1 or CS453-SHP1 as indicated. C, inhibition of SHP1-PTP in U937 cells increases gp91 PHOX and p67 PHOX mRNA abundance. U937 cells were stably transfected with SHP1, a dominant negative SHP1 (CS453), or control vector (pSR 𝛂 ). RNA was isolated, with or without 48-h IFN 𝛄 -induced differentiation, and analyzed by Northern blot for gp91 PHOX and p67 PHOX expression, as indicated. Blots were also probed for 𝛄 -actin, to control for RNA loading. SHP1 overexpression decreases gp91 PHOX and p67 PHOX mRNA abundance in differentiated U937 cells. Consistent with this, SHP1 inhibition increases gp91 PHOX and p67 PHOX mRNAin undifferentiated U937 cells. D, SHP1-PTP inhibition does not increase gp91 PHOX and p67 PHOX mRNA stability in U937 cells. U937 stable transfectants with CS453-SHP1 or vector control were treated with actinomycin D (10 𝛍 g/ml), and total RNA was isolated at t = 0, 2, 4, 6, and 8 h. RNA was analyzed by Northern blots probed for gp91 PHOX , p67 PHOX , and 𝛄 -actin (control message). MRNA abundance was determined by densitometry of Northern blot autoradiographs. Results are expressed relative to gp91 PHOX and p67 PHOX mRNA abundance at t = 0 and are normalized for 𝛄 -actin mRNA to control for loading. Data are shown for a representative blot. Although CS453-SHP1 overexpression increases abundance of gp91 PHOX and p67 PHOX mRNA, there is no change in the stability of the messages.
FIG. 2 Inhibition of SHP1-PTP activity increases gp91 PHOX and p67 PHOX mRNA abundance. A, SHP1-PTP protein is predominantly nuclear in U937 cells, and protein abundance decreases during IFN 𝛄 -induced differentiation. U937 cells were incubated for 48 h with or without IFN 𝛄 differentiation. Nuclear and cytoplasmic proteins were isolated and separated by SDS-PAGE (50 𝛍 g), and Western blots were probed with anti-SHP1 antibody. Nuclear ( NE ) and cytoplasmic ( CE ) fractions and IFN 𝛄 treatment are as indicated. IFN 𝛄 treatment results in modest decrease in nuclear SHP1 protein. B, SHP1 and CS453-SHP1 are overexpressed in U937 stable transfectants. U937 cells were stably transfected with vectors to overexpress SHP1, dominant negative SHP1 (CS453), or control pSR 𝛂 vector. Cell lysates were separated by SDSPAGE (10 𝛍 g) and probed with anti-SHP1 antibody. Increased immunoreactive SHP1 is present in cells overexpressing either SHP1 or CS453-SHP1 as indicated. C, inhibition of SHP1-PTP in U937 cells increases gp91 PHOX and p67 PHOX mRNA abundance. U937 cells were stably transfected with SHP1, a dominant negative SHP1 (CS453), or control vector (pSR 𝛂 ). RNA was isolated, with or without 48-h IFN 𝛄 -induced differentiation, and analyzed by Northern blot for gp91 PHOX and p67 PHOX expression, as indicated. Blots were also probed for 𝛄 -actin, to control for RNA loading. SHP1 overexpression decreases gp91 PHOX and p67 PHOX mRNA abundance in differentiated U937 cells. Consistent with this, SHP1 inhibition increases gp91 PHOX and p67 PHOX mRNAin undifferentiated U937 cells. D, SHP1-PTP inhibition does not increase gp91 PHOX and p67 PHOX mRNA stability in U937 cells. U937 stable transfectants with CS453-SHP1 or vector control were treated with actinomycin D (10 𝛍 g/ml), and total RNA was isolated at t = 0, 2, 4, 6, and 8 h. RNA was analyzed by Northern blots probed for gp91 PHOX , p67 PHOX , and 𝛄 -actin (control message). MRNA abundance was determined by densitometry of Northern blot autoradiographs. Results are expressed relative to gp91 PHOX and p67 PHOX mRNA abundance at t = 0 and are normalized for 𝛄 -actin mRNA to control for loading. Data are shown for a representative blot. Although CS453-SHP1 overexpression increases abundance of gp91 PHOX and p67 PHOX mRNA, there is no change in the stability of the messages.CC-BY · From the PDF
Image 3
CC-BY · From the PDF
Image 4
CC-BY · From the PDF
Image 5
CC-BY · From the PDF
FIG. 3 Inhibition of SHP1-PTP activity increases CYBB and NCF2 transcription via the homologous HAF1 cis elements. A, SHP1-PTP inhibition increases expression from reporter constructs with 470 bp of the CYBB promoter or 400 bp of the NCF2 promoter. U937 stable transfectants overexpressing SHP1, CS453-SHP1, or empty vector (pSR 𝛂 ) control were co-transfected with reporter constructs with either the proximal 470 bp of CYBB promoter, the proximal 400 bp of the NCF2 5 ′ flank, or empty vector control (p-CATE). Reporter gene assays were performed 48 h after transfection. Results are expressed as percent increase in CAT activity relative to empty pCATE vector. Overexpression of CS453-SHP1 significantly increases reporter expression from the CYBB promoter construct (143 ± 12.8%, n = 3, p = 0.026) and the NCF2 promoter construct (129 ± 10.4%, n = 3, p = 0.056). Consistent with this, SHP1 overexpression decreases expression from the CYBB promoter (41.8 ± 6.6%, n = 3, p = 0.174) and NCF2 promoter (39.4 ± 5.5%, n = 3, p = 0.196). Neither protein alters pCATE control vector expression. B, SHP1-PTP inhibition increases activation of the CYBB HAF1 cis element by PU.1, IRF1, and ICSBP. U937 stable transfectants overexpressing SHP1, CS453-SHP1, or empty vector (pSR 𝛂 ) control were co-transfected with vectors to overexpress PU.1, IRF1, and ICSBP and either an artificial promoter construct with four copies of the CYBB HAF1 cis element (p-cybbhafTATACAT) or empty vector control (p-TATACAT). Transfectants were incubated 48 h, with or without IFN 𝛄 , and reporter assays were performed. Results are expressed as percent increase in CAT activity relative to p-TATACAT vector control. Overexpression of CS453-SHP1 increases activation of the HAF1 cis element by PU.1, IRF1, and ICSBP in undifferentiated (79.6 ± 17.7%, n = 5, p = 0.027) and in IFN 𝛄 -treated U937 transfectants (38.6 ± 13.4%, n = 3, p = 0.103). Consistent with this, overexpression of SHP1 significantly decreases activation of the CYBB HAF1 cis element by PU.1, IRF1, and ICSBP in undifferentiated (49.3% + 13.3%, n = 5, p = 0.026) and in IFN 𝛄 -treated U937 transfectants (61.8 ± 19.6%, n = 3, p = 0.037). In contrast, overexpression of these proteins does not alter p-TATACAT expression. C, overexpression of CS453-SHP1 in U937 cells increases in vitro binding of the HAF1a complex to the CYBB HAF1 cis element. Nuclear proteins were isolated from U937 cells that were stably transfected with CS453-SHP1 or empty vector control (pSR 𝛂 ), with and without IFN 𝛄 -differentiation. EMSA was performed with the CYBB HAF1 cis element probe and nuclear proteins as indicated: lane 1, pSR 𝛂 control, no IFN 𝛄 ; lane 2, CS453-SHP1/pSR 𝛂 , no IFN 𝛄 ; lane 3, pSR 𝛂 control, 48 h of IFN 𝛄 ; lane 4,
FIG. 3 Inhibition of SHP1-PTP activity increases CYBB and NCF2 transcription via the homologous HAF1 cis elements. A, SHP1-PTP inhibition increases expression from reporter constructs with 470 bp of the CYBB promoter or 400 bp of the NCF2 promoter. U937 stable transfectants overexpressing SHP1, CS453-SHP1, or empty vector (pSR 𝛂 ) control were co-transfected with reporter constructs with either the proximal 470 bp of CYBB promoter, the proximal 400 bp of the NCF2 5 ′ flank, or empty vector control (p-CATE). Reporter gene assays were performed 48 h after transfection. Results are expressed as percent increase in CAT activity relative to empty pCATE vector. Overexpression of CS453-SHP1 significantly increases reporter expression from the CYBB promoter construct (143 ± 12.8%, n = 3, p = 0.026) and the NCF2 promoter construct (129 ± 10.4%, n = 3, p = 0.056). Consistent with this, SHP1 overexpression decreases expression from the CYBB promoter (41.8 ± 6.6%, n = 3, p = 0.174) and NCF2 promoter (39.4 ± 5.5%, n = 3, p = 0.196). Neither protein alters pCATE control vector expression. B, SHP1-PTP inhibition increases activation of the CYBB HAF1 cis element by PU.1, IRF1, and ICSBP. U937 stable transfectants overexpressing SHP1, CS453-SHP1, or empty vector (pSR 𝛂 ) control were co-transfected with vectors to overexpress PU.1, IRF1, and ICSBP and either an artificial promoter construct with four copies of the CYBB HAF1 cis element (p-cybbhafTATACAT) or empty vector control (p-TATACAT). Transfectants were incubated 48 h, with or without IFN 𝛄 , and reporter assays were performed. Results are expressed as percent increase in CAT activity relative to p-TATACAT vector control. Overexpression of CS453-SHP1 increases activation of the HAF1 cis element by PU.1, IRF1, and ICSBP in undifferentiated (79.6 ± 17.7%, n = 5, p = 0.027) and in IFN 𝛄 -treated U937 transfectants (38.6 ± 13.4%, n = 3, p = 0.103). Consistent with this, overexpression of SHP1 significantly decreases activation of the CYBB HAF1 cis element by PU.1, IRF1, and ICSBP in undifferentiated (49.3% + 13.3%, n = 5, p = 0.026) and in IFN 𝛄 -treated U937 transfectants (61.8 ± 19.6%, n = 3, p = 0.037). In contrast, overexpression of these proteins does not alter p-TATACAT expression. C, overexpression of CS453-SHP1 in U937 cells increases in vitro binding of the HAF1a complex to the CYBB HAF1 cis element. Nuclear proteins were isolated from U937 cells that were stably transfected with CS453-SHP1 or empty vector control (pSR 𝛂 ), with and without IFN 𝛄 -differentiation. EMSA was performed with the CYBB HAF1 cis element probe and nuclear proteins as indicated: lane 1, pSR 𝛂 control, no IFN 𝛄 ; lane 2, CS453-SHP1/pSR 𝛂 , no IFN 𝛄 ; lane 3, pSR 𝛂 control, 48 h of IFN 𝛄 ; lane 4,CC-BY · From the PDF
FIG. 4 IRF1 and ICSBP are tyrosine-phosphorylated during IFN 𝛄 -induced U937 differentiation. A, IFN 𝛄 differentiation does not alter nuclear versus cytoplasmic localization of IRF1 or ICSBP. U937 cells were incubated for 48 h, with or without IFN 𝛄 , as indicated. Nuclear and cytoplasmic protein fractions were isolated and separated by SDS-PAGE (30 𝛍 g), and Western-blotted proteins were serially probed with antibody to IRF1 and ICSBP as indicated. IFN 𝛄 treatment does not significantly alter the abundance of total or nuclear IRF1 or ICSBP. B, IFN 𝛄 differentiation of U937 cells increases abundance of tyrosine-phosphorylated IRF1 and ICSBP. U937 cells were incubated for 48 h, with or without IFN 𝛄 , as indicated. Nuclear proteins (200 𝛍 g) were immunoprecipitated with an anti-phosphotyrosine antibody (1.0 𝛍 g) or irrelevant, control antibody (mouse anti-rabbit IgG). Immunoprecipitated proteins were analyzed by Western blot with antibodies to IRF1 or ICSBP, as indicated. IFN 𝛄 treatment of U937 cells significantly increases the abundance of immunoprecipitable, tyrosine-phosphorylated IRF1 and ICSBP. C, IFN 𝛄 differentiation of U937 cells increases ICSBP tyrosine phosphorylation but not ICSBP protein abundance. U937 cells were incubated 48 h, with or without IFN 𝛄 , as indicated. Nuclear proteins (200 𝛍 g) were immunoprecipitated with an anti-ICSBP antibody (1.0 𝛍 g) or irrelevant, control antibody (goat anti-rabbit IgG). Immunoprecipitated proteins were analyzed by Western blot with anti-phosphotyrosine or anti-ICSBP antibodies, as indicated. IFN 𝛄 treatment of U937 cells significantly increases the abundance of tyrosine-phosphorylated ICSBP but not total ICSBP. D, IFN 𝛄 differentiation of U937 cells increases IRF1 tyrosine phosphorylation but not IRF1 protein abundance. U937 cells were incubated 48 h with or without IFN 𝛄 , as indicated. Nuclear proteins (200 𝛍 g) were immunoprecipitated with an anti-IRF1 antibody (1.0 𝛍 g) or irrelevant, control antibody (rabbit anti-mouse IgG). Immunoprecipitated proteins were analyzed by Western blot with anti-phosphotyrosine or anti-IRF1 antibodies, as indicated. IFN 𝛄 treatment of U937 cells significantly increases the abundance of tyrosine-phosphorylated IRF1 but not total IRF1. E, inhibition of SHP1-PTP increases tyrosine phosphorylation of IRF1 and ICSBP in undifferentiated U937 cells. Nuclear proteins were isolated from U937 stable transfectants with CS354-SHP1 or pSR 𝛂 control and immunoprecipitated (200 𝛍 g) with anti-phosphotyrosine antibody (1.0 𝛍 g) or irrelevant control antibody (mouse anti-rabbit IgG). Immunoprecipitated proteins were analyzed by Western blot with antibodies to IRF1 or ICSBP, as indicated. Overexpression of CS453-SHP1 in U937 cells increases IRF1 and ICSBP tyrosine phosphorylation. F, SHP1-PTP decreases tyrosine phosphorylation of in vitro translated IRF1 and ICSBP. U937 lysate proteins (200 𝛍 g) were immunoprecipitated with antibody to SHP1 (1.0 𝛍 g) or irrelevant antibody control (rabbit anti-mouse IgG). In vitro translated, 35 S-labeled IRF1 and ICSBP were incubated with either SHP1 or control eluate. The proteins were subsequently immunoprecipitated with anti-phosphotyrosine antibody (1.0 𝛍 g) or irrelevant antibody control (rabbit anti-mouse IgG). IRF protein immunoprecipitates were separated by SDS-PAGE and identified by autoradiography, as indicated. Incubation with SHP1 immunoprecipitate decreases tyrosine phosphorylation of IRF1 and ICSBP but does not decrease abundance of these proteins.
FIG. 4 IRF1 and ICSBP are tyrosine-phosphorylated during IFN 𝛄 -induced U937 differentiation. A, IFN 𝛄 differentiation does not alter nuclear versus cytoplasmic localization of IRF1 or ICSBP. U937 cells were incubated for 48 h, with or without IFN 𝛄 , as indicated. Nuclear and cytoplasmic protein fractions were isolated and separated by SDS-PAGE (30 𝛍 g), and Western-blotted proteins were serially probed with antibody to IRF1 and ICSBP as indicated. IFN 𝛄 treatment does not significantly alter the abundance of total or nuclear IRF1 or ICSBP. B, IFN 𝛄 differentiation of U937 cells increases abundance of tyrosine-phosphorylated IRF1 and ICSBP. U937 cells were incubated for 48 h, with or without IFN 𝛄 , as indicated. Nuclear proteins (200 𝛍 g) were immunoprecipitated with an anti-phosphotyrosine antibody (1.0 𝛍 g) or irrelevant, control antibody (mouse anti-rabbit IgG). Immunoprecipitated proteins were analyzed by Western blot with antibodies to IRF1 or ICSBP, as indicated. IFN 𝛄 treatment of U937 cells significantly increases the abundance of immunoprecipitable, tyrosine-phosphorylated IRF1 and ICSBP. C, IFN 𝛄 differentiation of U937 cells increases ICSBP tyrosine phosphorylation but not ICSBP protein abundance. U937 cells were incubated 48 h, with or without IFN 𝛄 , as indicated. Nuclear proteins (200 𝛍 g) were immunoprecipitated with an anti-ICSBP antibody (1.0 𝛍 g) or irrelevant, control antibody (goat anti-rabbit IgG). Immunoprecipitated proteins were analyzed by Western blot with anti-phosphotyrosine or anti-ICSBP antibodies, as indicated. IFN 𝛄 treatment of U937 cells significantly increases the abundance of tyrosine-phosphorylated ICSBP but not total ICSBP. D, IFN 𝛄 differentiation of U937 cells increases IRF1 tyrosine phosphorylation but not IRF1 protein abundance. U937 cells were incubated 48 h with or without IFN 𝛄 , as indicated. Nuclear proteins (200 𝛍 g) were immunoprecipitated with an anti-IRF1 antibody (1.0 𝛍 g) or irrelevant, control antibody (rabbit anti-mouse IgG). Immunoprecipitated proteins were analyzed by Western blot with anti-phosphotyrosine or anti-IRF1 antibodies, as indicated. IFN 𝛄 treatment of U937 cells significantly increases the abundance of tyrosine-phosphorylated IRF1 but not total IRF1. E, inhibition of SHP1-PTP increases tyrosine phosphorylation of IRF1 and ICSBP in undifferentiated U937 cells. Nuclear proteins were isolated from U937 stable transfectants with CS354-SHP1 or pSR 𝛂 control and immunoprecipitated (200 𝛍 g) with anti-phosphotyrosine antibody (1.0 𝛍 g) or irrelevant control antibody (mouse anti-rabbit IgG). Immunoprecipitated proteins were analyzed by Western blot with antibodies to IRF1 or ICSBP, as indicated. Overexpression of CS453-SHP1 in U937 cells increases IRF1 and ICSBP tyrosine phosphorylation. F, SHP1-PTP decreases tyrosine phosphorylation of in vitro translated IRF1 and ICSBP. U937 lysate proteins (200 𝛍 g) were immunoprecipitated with antibody to SHP1 (1.0 𝛍 g) or irrelevant antibody control (rabbit anti-mouse IgG). In vitro translated, 35 S-labeled IRF1 and ICSBP were incubated with either SHP1 or control eluate. The proteins were subsequently immunoprecipitated with anti-phosphotyrosine antibody (1.0 𝛍 g) or irrelevant antibody control (rabbit anti-mouse IgG). IRF protein immunoprecipitates were separated by SDS-PAGE and identified by autoradiography, as indicated. Incubation with SHP1 immunoprecipitate decreases tyrosine phosphorylation of IRF1 and ICSBP but does not decrease abundance of these proteins.CC-BY · From the PDF
FIG. 5 Conserved tyrosine residues in IRF1 and ICSBP are necessary for protein-protein interactions that activate CYBB and NCF2 transcription. A, the conserved tyrosine residues in IRF1 (Tyr-109) and ICSBP (Tyr-95) are necessary for activation of the CYBB HAF1 cis element. U937 cells were co-transfected with an artificial promoter construct with multiple copies of the CYBB HAF1 cis element (p-cybbhafTATACAT), or control (p-TATACAT), and vectors to overexpress various combinations of PU.1, IRF1 or Y109F IRF1, and ICSBP or Y95F ICSBP. Results are expressed as percent increased CAT activity, relative to p-TATACAT vector control. Reporter expression from pcybbhafTATACAT was not significantly different with overexpression of PU.1 + IRF1 than with PU.1 + Y109F IRF1 ( n = 14, p = 0.745). Additionally, p-cybbhafTATACAT expression was not significantly different with overexpression of PU.1 + Y109F IRF1 + ICSBP than with PU.1 + ICSBP ( n = 12, p = 0.34). In contrast, p-cybbhafTATACAT expression was not significantly different with overexpression of PU.1 than with PU.1 + Y95F ICSBP ( n = 12, p = 0.32). Additionally, p-cybbhafTATACAT expression was not significantly different with overexpression of PU.1 + IRF1 + Y95F ICSBP than with PU.1 + IRF1 ( n = 12, p = 0.38). Consistent with our previous results, these proteins had no effect on p-TATACAT reporter expression. B, the conserved tyrosine residues in IRF1 (Tyr-109) and ICSBP (Tyr-95) are necessary for IFN 𝛄 -induced activation of the CYBB HAF1 cis element. U937 cells were co-transfected with an artificial promoter construct with multiple copies of the CYBB HAF1 cis element (p-cybbhafTATACAT), or control (p-TATACAT), and vectors to overexpress various combinations of PU.1, IRF1 or Y109F IRF1, and ICSBP or Y95F ICSBP. Results are expressed as percent increase in CAT activity, relative to p-TATACAT control. Consistent with our previous results, IFN 𝛄 differentiation significantly increases p-cybbhafTATACAT expression in U937 transfectants overexpressing PU.1 + IRF1 + ICSBP. In contrast, IFN 𝛄 differentiation does not increase p-cybbhafTATACAT expression in U937 transfectants overexpressing PU.1 + IRF1 + Y95F ICSBP, PU.1 + Y109F IRF1 + ICSBP, or PU.1 + Y109F IRF1 + Y95F ICSBP. C, overexpressed ICSBP is tyrosine-phosphorylated during IFN 𝛄 differentiation of U937 cells. U937 cells, stably transfected with epitope-tagged ICSBP, were incubated 48 h, with or without IFN 𝛄 , as indicated. Nuclear proteins (200 𝛍 g) were immunoprecipitated with an anti-' xpress ' tag antibody (1.0 𝛍 g), or irrelevant, control antibody (mouse anti-rabbit IgG). Immunoprecipitated proteins were analyzed by Western blot with anti-phosphotyrosine and anti-' xpress ' antibodies, as indicated. IFN 𝛄 treatment of U937 cells significantly increases tyrosine phosphorylation of overexpressed ICSBP.
FIG. 5 Conserved tyrosine residues in IRF1 and ICSBP are necessary for protein-protein interactions that activate CYBB and NCF2 transcription. A, the conserved tyrosine residues in IRF1 (Tyr-109) and ICSBP (Tyr-95) are necessary for activation of the CYBB HAF1 cis element. U937 cells were co-transfected with an artificial promoter construct with multiple copies of the CYBB HAF1 cis element (p-cybbhafTATACAT), or control (p-TATACAT), and vectors to overexpress various combinations of PU.1, IRF1 or Y109F IRF1, and ICSBP or Y95F ICSBP. Results are expressed as percent increased CAT activity, relative to p-TATACAT vector control. Reporter expression from pcybbhafTATACAT was not significantly different with overexpression of PU.1 + IRF1 than with PU.1 + Y109F IRF1 ( n = 14, p = 0.745). Additionally, p-cybbhafTATACAT expression was not significantly different with overexpression of PU.1 + Y109F IRF1 + ICSBP than with PU.1 + ICSBP ( n = 12, p = 0.34). In contrast, p-cybbhafTATACAT expression was not significantly different with overexpression of PU.1 than with PU.1 + Y95F ICSBP ( n = 12, p = 0.32). Additionally, p-cybbhafTATACAT expression was not significantly different with overexpression of PU.1 + IRF1 + Y95F ICSBP than with PU.1 + IRF1 ( n = 12, p = 0.38). Consistent with our previous results, these proteins had no effect on p-TATACAT reporter expression. B, the conserved tyrosine residues in IRF1 (Tyr-109) and ICSBP (Tyr-95) are necessary for IFN 𝛄 -induced activation of the CYBB HAF1 cis element. U937 cells were co-transfected with an artificial promoter construct with multiple copies of the CYBB HAF1 cis element (p-cybbhafTATACAT), or control (p-TATACAT), and vectors to overexpress various combinations of PU.1, IRF1 or Y109F IRF1, and ICSBP or Y95F ICSBP. Results are expressed as percent increase in CAT activity, relative to p-TATACAT control. Consistent with our previous results, IFN 𝛄 differentiation significantly increases p-cybbhafTATACAT expression in U937 transfectants overexpressing PU.1 + IRF1 + ICSBP. In contrast, IFN 𝛄 differentiation does not increase p-cybbhafTATACAT expression in U937 transfectants overexpressing PU.1 + IRF1 + Y95F ICSBP, PU.1 + Y109F IRF1 + ICSBP, or PU.1 + Y109F IRF1 + Y95F ICSBP. C, overexpressed ICSBP is tyrosine-phosphorylated during IFN 𝛄 differentiation of U937 cells. U937 cells, stably transfected with epitope-tagged ICSBP, were incubated 48 h, with or without IFN 𝛄 , as indicated. Nuclear proteins (200 𝛍 g) were immunoprecipitated with an anti-' xpress ' tag antibody (1.0 𝛍 g), or irrelevant, control antibody (mouse anti-rabbit IgG). Immunoprecipitated proteins were analyzed by Western blot with anti-phosphotyrosine and anti-' xpress ' antibodies, as indicated. IFN 𝛄 treatment of U937 cells significantly increases tyrosine phosphorylation of overexpressed ICSBP.CC-BY · From the PDF
FIG. 6 Conserved tyrosine residues in IRF1 and ICSBP increase the affinity of protein-protein interactions. A, PU.1 has equivalent affinity for IRF1 and Y109F IRF1. PU.1/GST and control GST were analyzed for binding of in vitro translated, [ 35 S]methioninelabeled IRF1 or Y109F IRF1. Binding assays were also incubated with either control reticulocyte lysate, in vitro translated unlabeled ICSBP, or Y95F ICSBP, as indicated. Precipitating proteins were separated by SDS-PAGE, and co-precipitation of IRF1 or Y109F IRF1 with PU.1/GST or GST was detected by autoradiography. IRF1 and Y109F IRF1 bind PU.1/GST (but not control GST) with equal affinity, and binding affinity is not altered by ICSBP. B, PU.1 has greater affinity for ICSBP than for Y95F ICSBP. PU.1/GST and control GST were analyzed for binding of in vitro translated, [ 35 S]methionine-labeled ICSBP or Y95F ICSBP. Binding assays were incubated with either control reticulocyte lysate, in vitro translated, unlabeled IRF1, or Y109F IRF1, as indicated. Precipitating proteins were separated by SDS-PAGE, and co-precipitation of ICSBP or Y95F ICSBP with PU.1/GST or GST was detected by autoradiography. ICSBP binds PU.1/GST (but not control GST) with greater affinity than Y95F ICSBP. Binding affinity of both ICSBP and Y95F ICSBP for PU.1/GST is slightly increased by IRF1 but not Y109F IRF1. C, IRF1 has greater affinity for ICSBP than for Y95F ICSBP, and Tyr-109 mutant IRF1 has less affinity for ICSBP than does wild type IRF1. IRF1/GST, Y109F IRF1/GST, and control GST were analyzed for binding of in vitro translated, [ 35 S]methionine-labeled ICSBP or Y95F ICSBP, as indicated. Precipitating proteins were separated by SDSPAGE, and co-precipitation of ICSBP or Y95F ICSBP with IRF1/GST, Y109F IRF1/GST, or GST was detected by autoradiography. ICSBP binds IRF1/GST with greater affinity than Y95F ICSBP, and neither in vitro translated protein co-precipitates efficiently with Y109F IRF1/ GST. D, Y109F IRF1 does not participate in the HAF1 complex binding the CYBB HAF1 cis element, and Y95F ICSBP does not participate in either the HAF1 or HAF1a complex. U937 cells were transfected with a vector to overexpress epitope-tagged IRF1 ( lanes 1 and 2 ), ICSBP ( lanes 3 and 4 ), Y109F IRF1 ( lanes 5 and 6 ), or Y95F ICSBP ( lanes 7 and 8 ). Transfectants were treated with IFN 𝛄 for 48 h, and nuclear proteins were used in EMSA with the CYBB HAF1 cis element probe. Binding reactions were preincubated with either anti-' xpress ' epitope antibody ( lanes 2, 4, 6, and 8 ) or irrelevant, control antibody ( lanes 1, 3, 5, and 7 ). The HAF1 complex is indicated by the arrow and the HAF1a complex by the arrowhead. Epitope-tagged IRF1 and ICSBP are present in the HAF1 and HAF1a complexes, consistent with our previous results with endogenous proteins. However, Y109F IRF1 is only present in the HAF1 complex, and Y95F ICSBP is not present in either the HAF1 or HAF1a complex.
FIG. 6 Conserved tyrosine residues in IRF1 and ICSBP increase the affinity of protein-protein interactions. A, PU.1 has equivalent affinity for IRF1 and Y109F IRF1. PU.1/GST and control GST were analyzed for binding of in vitro translated, [ 35 S]methioninelabeled IRF1 or Y109F IRF1. Binding assays were also incubated with either control reticulocyte lysate, in vitro translated unlabeled ICSBP, or Y95F ICSBP, as indicated. Precipitating proteins were separated by SDS-PAGE, and co-precipitation of IRF1 or Y109F IRF1 with PU.1/GST or GST was detected by autoradiography. IRF1 and Y109F IRF1 bind PU.1/GST (but not control GST) with equal affinity, and binding affinity is not altered by ICSBP. B, PU.1 has greater affinity for ICSBP than for Y95F ICSBP. PU.1/GST and control GST were analyzed for binding of in vitro translated, [ 35 S]methionine-labeled ICSBP or Y95F ICSBP. Binding assays were incubated with either control reticulocyte lysate, in vitro translated, unlabeled IRF1, or Y109F IRF1, as indicated. Precipitating proteins were separated by SDS-PAGE, and co-precipitation of ICSBP or Y95F ICSBP with PU.1/GST or GST was detected by autoradiography. ICSBP binds PU.1/GST (but not control GST) with greater affinity than Y95F ICSBP. Binding affinity of both ICSBP and Y95F ICSBP for PU.1/GST is slightly increased by IRF1 but not Y109F IRF1. C, IRF1 has greater affinity for ICSBP than for Y95F ICSBP, and Tyr-109 mutant IRF1 has less affinity for ICSBP than does wild type IRF1. IRF1/GST, Y109F IRF1/GST, and control GST were analyzed for binding of in vitro translated, [ 35 S]methionine-labeled ICSBP or Y95F ICSBP, as indicated. Precipitating proteins were separated by SDSPAGE, and co-precipitation of ICSBP or Y95F ICSBP with IRF1/GST, Y109F IRF1/GST, or GST was detected by autoradiography. ICSBP binds IRF1/GST with greater affinity than Y95F ICSBP, and neither in vitro translated protein co-precipitates efficiently with Y109F IRF1/ GST. D, Y109F IRF1 does not participate in the HAF1 complex binding the CYBB HAF1 cis element, and Y95F ICSBP does not participate in either the HAF1 or HAF1a complex. U937 cells were transfected with a vector to overexpress epitope-tagged IRF1 ( lanes 1 and 2 ), ICSBP ( lanes 3 and 4 ), Y109F IRF1 ( lanes 5 and 6 ), or Y95F ICSBP ( lanes 7 and 8 ). Transfectants were treated with IFN 𝛄 for 48 h, and nuclear proteins were used in EMSA with the CYBB HAF1 cis element probe. Binding reactions were preincubated with either anti-' xpress ' epitope antibody ( lanes 2, 4, 6, and 8 ) or irrelevant, control antibody ( lanes 1, 3, 5, and 7 ). The HAF1 complex is indicated by the arrow and the HAF1a complex by the arrowhead. Epitope-tagged IRF1 and ICSBP are present in the HAF1 and HAF1a complexes, consistent with our previous results with endogenous proteins. However, Y109F IRF1 is only present in the HAF1 complex, and Y95F ICSBP is not present in either the HAF1 or HAF1a complex.CC-BY · From the PDF

Verification

Claims the paper makes

1 Valid · 0 Not valid · 15 Not checked · 112 Own results and interpretations

83 more claims

Create a free account to see all 128 claims and to verify the 24 references still open.

See all claims — free account
  • It may state two separate claims as one. 30
  • Probably not a substantial claim. 12

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 37 references

Research works printed but not linked: 2

  1. Tapley, P., Shevde, N. K., Schweitzer, P. A., Gallina, M., Christianson, S. W., Lin, I. L., Stein, R. B., Shultz, L. D., Rosen, J., and Lamb, P. (1997) Exp. Hematol. 25, 122-131
  2. Chomszynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156 -159

Cited by

See all 61

Metadata

Authors
Kautz, B., Kakar, R., David, E., & Eklund, E. A.
Affiliations
  • Northwestern University (US)
  • University of Alabama at Birmingham (US)
Corresponding author
Eklund, Elizabeth A.
Venue
Journal of Biological Chemistry
Published
2001-10
Volume
276
Issue
41
Pages
37868-37878
ISSN
0021-9258 (ISSN-L)
OpenAlex
W1514864149
Cited by
61
References
37
Citations by year
2025: 1 · 2024: 1 · 2022: 1 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 2 · 2013: 1 · 2012: 3
FWCI
2.08
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (HL 5400)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Immunology and Microbiology › Immunology › Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords
gp91phox, p67phox, CYBB, NCF2, respiratory burst oxidase, myeloid differentiation, PU.1, IRF1, CREB-binding protein, transcriptional regulation, tyrosine phosphorylation, interferon-gamma
MeSH terms
NADPH Oxidase 2, Base Sequence, Humans, Membrane Glycoproteins, Phosphoproteins, Phosphorylation, Protein Binding, RNA, Messenger, Transcription Factors, Transcription, Genetic, Gene Expression Regulation, Enzymologic, Mutagenesis, Site-Directed, DNA Primers, NADPH Oxidases, U937 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SHP1 Protein-tyrosine Phosphatase Inhibits gp91PHOXand p67PHOX Expression by Inhibiting Interaction of PU.1, IRF1, Interferon Consensus Sequence-binding Protein, and CREB-binding Protein with Homologous Cis Elements in the CYBB andNCF2 Genes. https://app.cochat.ai/papers/10.1074/jbc.m103381200
The paper
Kautz, B., Kakar, R., David, E., & Eklund, E. A. (2001). SHP1 Protein-tyrosine Phosphatase Inhibits gp91PHOXand p67PHOX Expression by Inhibiting Interaction of PU.1, IRF1, Interferon Consensus Sequence-binding Protein, and CREB-binding Protein with Homologous Cis Elements in the CYBB andNCF2 Genes. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m103381200

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.